<DOC>
	<DOCNO>NCT02943798</DOCNO>
	<brief_summary>The primary endpoint compare PFS ( progress-free survival ) etoposide plus carboplatin paclitaxel combine carboplatin first-line treatment advance pulmonary large cell neuroendocrine carcinoma .</brief_summary>
	<brief_title>Optimization Treatment Advanced Pulmonary Large Cell Neuroendocrine Carcinoma</brief_title>
	<detailed_description>The primary endpoint compare PFS ( progress-free survival ) etoposide plus carboplatin paclitaxel combine carboplatin first-line treatment advance pulmonary large cell neuroendocrine carcinoma . In addition , gene spectrum detection Mini-PDX apply validation pharmacodynamic . Results clinical trial pharmacodynamic test analyze provide evidence precise treatment LCNEC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Stage IIIB IV pulmonary largecell neuroendocrine carcinoma confirm histology cytology Estimated life expectancy 3 month Performance status 0,1,2 Signed inform consent Adequate organ function : absolute neutrophil count ( ANC ) 1,500 cells/mm3 ( 1.5 x 109/L ) ; platelet count over100,000/mm3 ( 100 x 109/L ) ; serum creatinine &lt; 2.5 mg/dL ( 221 mmol/L ) ; serum AST ALT &lt; 5.0 x upper limit normal ( ULN ) ; serum total bilirubin &lt; 2.0 mg/dL ( 34 mmol/L ) History chemotherapy molecular target therapy Thoracic radical radiotherapy within 28 day initiation study drug therapy except palliative radiotherapy Use standard/experimental anticancer drug therapy within 28 day initiation study drug therapy Prior history malignancy nonsmall cell lung cancer ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease &gt; = 1 year Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Pregnant lactating Patient concurrent medical psychiatric illness would , opinion investigator , prevent compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Large Cell Neuroendocrine Carcinoma , chemotherapy</keyword>
</DOC>